Dr Philip Camilleri was appointed as Consultant Clinical Oncologist in 2006 having trained in clinical oncology in Oxford. He specialises in urological cancers – specifically prostate, bladder, renal and testicular cancers – and provides chemotherapy, hormonal as well as radiotherapy treatment to cover all situations.
He is involved in research for most urological cancers and has opened up and led on numerous national studies in Oxford.
Dr Camilleri set up the prostate brachytherapy service in Oxford in 2013. He is the lead clinician for the urological oncology multi-disciplinary team at the Churchill Hospital.
Consultant Clinical Oncologist, Oxford Cancer Centre and Oxford University Hospitals NHS Trust.
MRCP M.D. FRCR
Technical radiotherapy with brachytherapy, stereotactic hypofractionated radiotherapy, image guided therapy as well as targeted therapy using advanced imaging techniques.
Special clinical interest in urological cancers with a special interest in prostate cancer. Other tumours treated include testicular; bladder and renal cancer. Radical urological oncology treatments with intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), brachytherapy and stereotactic ablative body radiotherapy (SABR).
Systemic therapy including chemotherapy with docetaxel and cabazitaxel; hormone therapy including abiraterone (Zytiga) and enzalutamide (Xtandi); bone therapy with Radium 223, Zometa and Denosumab. Palliative radiotherapy and SABR for oligometastatic disease.
Kay Fellowship awarded by the Royal College of Radiologists 2013.